Reviva Pharmaceuticals (RVPH) S-1/A 10 May 21 2020 FY IPO registration (amended) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020
Document Information [Line Items]
Entity Registrant Name	REVIVA PHARMACEUTICALS HOLDINGS, INC.
Entity Central Index Key	0001742927
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true
Document Type	S-1/A
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	true
Amendment Description	Amendment 1

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Assets
Cash	$ 8,760,462	$ 193
Property and equipment, net		591
Lease deposit	1,816	1,816
Total assets	8,762,278	2,600
Liabilities
Accounts payable	1,008,046	224,543
Accrued expenses and other current liabilities	324,697	2,722,875
Warrant liabilities	1,963,785	101,525
Convertible promissory notes, net		3,765,087
Total liabilities	3,296,528	6,814,030
Commitments and contingencies (Note 11)
Stockholders’ equity (deficit)
Common stock, par value of $0.0001; 115,000,000 shares authorized; 9,231,737 shares issued and outstanding at December 31, 2020	923	618
Additional paid-in capital	63,774,920	18,644,683
Accumulated deficit	(58,310,093)	(54,526,705)
Total stockholders’ equity (deficit)	5,465,750	(6,811,430)
Total Liabilities and Stockholders’ equity (deficit)	8,762,278	2,600
Series 1 Convertible Preferred Stock [Member]
Stockholders’ equity (deficit)
Preferred stock		3,069,913
Series 2 Convertible Preferred Stock [Member]
Stockholders’ equity (deficit)
Preferred stock		7,624,841
Series 3 Convertible Preferred Stock [Member]
Stockholders’ equity (deficit)
Preferred stock		7,973,720
Series 4 Convertible Preferred Stock [Member]
Stockholders’ equity (deficit)
Preferred stock		$ 10,401,500

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Preferred stock, shares designated (in shares)	10,000,000
Preferred stock, shares outstanding (in shares)	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	115,000,000	115,000,000
Common stock, shares issued (in shares)	9,231,737
Common stock, shares outstanding (in shares)	9,231,737
Series 1 Convertible Preferred Stock [Member]
Preferred stock, shares designated (in shares)		95,204
Preferred stock, shares issued (in shares)		95,204
Preferred stock, shares outstanding (in shares)		95,204
Series 2 Convertible Preferred Stock [Member]
Preferred stock, shares designated (in shares)		189,709
Preferred stock, shares issued (in shares)		189,709
Preferred stock, shares outstanding (in shares)		189,709
Series 3 Convertible Preferred Stock [Member]
Preferred stock, shares designated (in shares)		144,923
Preferred stock, shares issued (in shares)		144,923
Preferred stock, shares outstanding (in shares)		144,923
Series 4 Convertible Preferred Stock [Member]
Preferred stock, shares designated (in shares)		761,340
Preferred stock, shares issued (in shares)		156,835
Preferred stock, shares outstanding (in shares)		156,835

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating expenses
Research and development	$ 295,150	$ 195,744
General and administrative	2,139,501	181,116
Total operating expenses	2,434,651	376,860
Loss from operations	(2,434,651)	(376,860)
Other income (expense)
Interest and other income, net	105,183	201
Interest expense	(1,453,120)	(469,373)
Total other (expense), net	(1,347,937)	(469,172)
Loss before provision for income taxes	(3,782,588)	(846,032)
Provision for income taxes	800	800
Net loss	$ (3,783,388)	$ (846,832)
Net loss per share:
Basic and diluted (in dollars per share)	$ (1.24)	$ (0.31)
Weighted average shares outstanding Basic and diluted (in shares)	3,061,670	2,768,346

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2018	1,597,585	2,768,346
Balance at Dec. 31, 2018	$ 29,069,974	$ 618	$ 18,644,683	$ (53,679,873)	$ (5,964,598)
Net loss				(846,832)	(846,832)
Balance (in shares) at Dec. 31, 2019	1,597,585	2,768,346
Balance at Dec. 31, 2019	$ 29,069,974	$ 618	18,644,683	(54,526,705)	(6,811,430)
Net loss				(3,783,388)	(3,783,388)
Issuance of common stock in lieu of deferred compensation (in shares)		38,992
Issuance of common stock in lieu of deferred compensation		$ 25	340,907		340,932
Beneficial conversion feature on conversion of notes payable			961,680		961,680
Issuance of common stock upon conversion of notes and accrued interest (in shares)		1,099,947
Issuance of common stock upon conversion of notes and accrued interest		$ 110	8,499,233		8,499,343
Reclassification of warrant liability			1,185,577		1,185,577
Proceeds from reverse acquisition, net of costs			9,375,961		9,375,961
Effect of reverse recapitalization, net of costs (in shares)	(1,597,585)	5,324,452
Effect of reverse recapitalization, net of costs	$ (29,069,974)	$ 170	24,766,879		(4,302,928)
Balance (in shares) at Dec. 31, 2020		9,231,737
Balance at Dec. 31, 2020		$ 923	$ 63,774,920	$ (58,310,093)	$ 5,465,750

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (3,783,388)	$ (846,832)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	591	645
Change in fair value of warrant liability	1,084,052	(6,409)
Noncash interest expense	961,680
Issuance of common stock in lieu of deferred compensation, net of gain	340,932
Changes in operating assets and liabilities
Deferred costs	(2,330,738)
Accounts payable	775,101	158,172
Accrued expenses and other current liabilities	(773,922)	475,980
Net cash used in operating activities	(3,725,692)	(218,444)
Cash flows from financing activities
Proceeds from issuance of convertible promissory notes	3,110,000	100,000
Proceeds from business combination, net of costs	9,375,961
Net cash provided by financing activities	12,485,961	100,000
Net increase (decrease) in cash	8,760,269	(118,444)
Cash, beginning of year	193	118,637
Cash, end of year	8,760,462	193
Supplemental disclosures of cash flow information:
Cash paid for taxes	800	800
Cash paid for interest	327,076
Supplemental schedule of noncash financing and investing activities:
Conversion of convertible promissory note into accrued legal liability		1,200,000
Conversion of convertible promissory notes into common stock	6,875,088
Payment of certain deferred costs from proceeds from business combination	$ 1,000,000

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. On December 14, 2020, July 20, 2020 Reviva Pharmaceuticals, Inc. was originally incorporated in the state of Delaware and commenced operations on May 1, 2006 2014.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company's financial statements. Such financial statements and accompanying notes are the representations of Company's management, who is responsible for their integrity and objectivity. Principals of consolidation The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation. Restatement of previously issued financial statements As part of the Business Combination, the Company originally completed a comprehensive evaluation that supported the equity classification of the private warrants that were initially issued by Tenzing. Subsequent to filing our original report on March 21, 2021, April 12, 2021. 815, 815 815” December 14, 2020 December 31, 2020. $2.0 December 14, 2020. December 31, 2020 December 31, 2020 not not The table below sets forth the consolidated balance sheet for affected financial statement line items, balances originally reported as of December 31, 2020: As of December 31, 2020 Reported Restated Warrant liabilities $ - $ 1,963,785 Total liabilities 1,332,743 3,296,528 Additional paid-in capital 65,738,705 63,774,920 Total stockholders' equity (deficit) 7,429,535 5,465,750 In addition to the restated consolidated financial statement, the information contained in Notes 9 Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company's cash are held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may Cash The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of three December 31, 2020, 2019, two may, Property and equipment The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one 1 2 three five Leases In February 2016, 2016 2 no Research and development costs Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not General and Administrative costs General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not Income taxes The Company utilizes FASB ASC 740, not” not The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% not Stock-based compensation Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC 718 505, 50, The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under: • Expected term ​ • Expected volatility ​ • Expected dividend no ​ • Risk-free interest rate zero ​ As of January 1, 2019, No. 2018 07, 718 not not Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values. Fair Value Measurements of Warrants ASC 820 820 820 1 2 three 1 3 The three 820 • Level 1 — Quoted 1 ​ • Level 2 — Directly not 2 not ​ • Level 3 — Unobservable no ​ In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis as of December 31, 2020 Description Level December 31, 2020 Warrant liabilities 2 1,973,785 The key inputs used in valuing the warrant liabilities are as follows: Risk-free interest rate - 0.36% Expected life – 5 Expected volatility – 56.6% Exercise price – $11.50 Stock price – $8.75 Beneficial Conversion Features In accordance with FASB ASC 470 20,

Note 3 - Business Combination

Note 3 - Business Combination	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Business Combination Disclosure [Text Block]	3. On December 14, 2020, July 20, 2020 Upon the closing of the Business Combination, all shares of Reviva Pharmaceuticals, Inc. common stock and preferred stock issuance and outstanding immediately prior to the Business Combination converted into common stock of Reviva Pharmaceuticals Holdings, Inc., with a par value of $0.0001 0.152268 0.414647 0.152268. 0.152268. In addition to the merger consideration set forth above, the Reviva Pharmaceuticals, Inc. Security holders also have a contingent right to receive up to an additional 1,000,000 three 3 ● the closing price of the Company's common stock has to be equal to or greater than $15.00 20 30 ● the Company must receive positive data from (i) its first 3 2 The Business Combination was accounted for as a reverse merger in accordance with U.S. GAAP. Under this method of accounting, Tenzing is treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the holders of Reviva Pharmaceuticals, Inc. having a majority of the voting power of the post-combination company, Reviva Pharmaceuticals, Inc. senior management comprising substantially all of the senior management of the post-combination company, the relative size of Reviva compared to Tenzing, and Reviva Pharmaceuticals, Inc. operations comprising the ongoing operations of the post-combination company. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Reviva Pharmaceuticals, Inc. issuing stock for the net assets of Tenzing, accompanied by a recapitalization. The net assets of Tenzing are stated at historical cost, with no The accompanying financial statements and related notes reflect the historical results of Reviva Pharmaceuticals, Inc. prior to the merger and do not

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Property and equipment, net consist of the following: ​ 2020 2019 Computer equipment $ 32,500 $ 32,500 Furniture and fixtures 9,208 9,208 Accumulated depreciation (41,708 ) (41,117 ) Property and equipment, net $ - $ 591 Depreciation expense for the years ended December 31, 2020 2019 $591 $645

Note 5 - Employee Benefit Plan

Note 5 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	5. In 2014, 401 no December 31, 2020.

Note 6 - Convertible Promissory

Note 6 - Convertible Promissory Notes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	6. 2016 From June 2016 April 2017, $4,795,088 “2016 $5,000,000, 2016 not 20% $85,000,000 Interest was initially accrued at 8% 2016 twelve 2016 2017 12% December 31, 2019, $3,490,087 $1,192,496 The original stated conversion term for the 2016 not 20% $85 2016 On December 10, 2020, 2016 2016 $1,200,000 one 3,788,461 $1.329698. 576,836 no 2016 none. On January 2, 2020, 2016 2016 $1,200,000, $242,236, $5,000. $1,447,236 5.5% $79,840 2018 From November 2018 January 2019, $275,000 “2018 2018 not 2018 20% Additionally, the holders of the 2018 “2018 5 no December 31, 2019. Interest on the 2018 8% 2018 six six 2018 six 2018 8% On December 10, 2020, 2018 2018 370,811 $0.831018 2018 $50,000 2018 $1.330045 2018 $50,000 2018 56,461 no 2018 $159,025 2020 From March May 2020, $610,000 “2020 2020 not 2020 20% Additionally, the holders of the 2020 “2020 5 2020 2020 “2020 On December 10, 2020, 2020 2020 744,916 $0.831009 2020 $50,000 2020 $1.329770 2020 $50,000 2020 113,422 no 2020 no $317,730 Between August 2020 October 2020, $500,000 601,632 $0.831063. $274,083 In addition, the Company entered into a contingent capital commitment with certain investors for $2,000,000 1,718,280 $1.163953. 261,626 no $210,842

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	7. As a result of the Company's history of net operating losses and full valuation allowance against its deferred tax assets, there was no December 31, 2020 2019. Reconciliations to the statutory federal income tax rate and the Company's effective tax rate consist of the following: December 31, 2020 2019 Statutory federal income tax rate (794,343 ) (177,562 ) State income taxes, net of federal tax benefits (114,864 ) (79,257 ) Stock Based Compensation - 27,940 Foreign Rate Differential (45 ) - Warrant Expense 227,651 - Beneficial conversion feature related to notes 201,953 - Other Permanent Differences 19,204 473 Valuation allowance 461,244 229,206 800 800 The components of deferred tax assets included on the balance sheet are: December 31, 2020 2019 NOL carryforwards 9,177,607 8,711,765 Accruals and reserves 10,898 14,402 Stock compensation 237,976 83,472 Fixed assets/capitalized start-up costs 3,332 3,589 9,429,813 8,813,228 Valuation allowance (9,429,813 ) (8,813,228 ) Net deferred tax assets - - Deferred income taxes - - The Company has established a full valuation allowance against its deferred tax assets due to the uncertainty surrounding realization of such assets. Total increase in valuation allowance is $616,858 December 31, 2020. The Company currently has net operating loss carryforwards of approximately $39.5 $12.6 $35.3 2029. 2018 may 100% As of December 31, 2020 2019, no The Tax Reform Act of 1986 The Company has elected to recognize interest and penalties related to uncertain tax positions as components of income tax expense. As of December 31, 2020 2019, no The Company's income tax returns for all years remain open to examination by federal and state taxing authorities. The Company does not 12 As of December 31, 2020 2019, no On March 27, 2020, 2019 first 2020, 2019 2020. 163 30% 50% no

Note 8 - Loss Per Share

Note 8 - Loss Per Share	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Earnings Per Share [Text Block]	8. Loss per share calculations for all periods prior to the Business Combination have been retrospectively adjusted for the equivalent number of shares outstanding immediately after the Business Combination to effect the reverse recapitalization. Subsequent to the Business Combination, earnings per share will be calculated based on the weighted average shares of common stock then outstanding. Basic and dilutive net loss per share is computed by dividing the net loss for the period by the weighted average number of common stock outstanding during the period. The weighted average shares of common stock outstanding is based on the 9,231,737 For the years ended December 31, 2020 2019, 7,007,581 65,471 10, 1,000,000 not

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Deficit) (Restated)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Our authorized capital stock consists of: ● 115,000,000 $0.0001 ● 10,000,000 $0.0001 As of December 31, 2020, 9,231,737 no September 2020, 38,992 Common Stock Voting. The holders of our common stock are entitled to one Dividends. The holders of common stock are entitled to receive, ratably, dividends only if, when and as declared by our board of directors out of funds legally available therefor and after provision is made for each class of capital stock having preference over the common stock. Liquidation Rights. In the event of the Company's liquidation, dissolution or winding-up, the holders of common stock will be entitled to share, ratably, in all assets remaining available for distribution after payment of all liabilities and after provision is made for each class of capital stock having preference over the Common Stock. Conversion Right. The holders of common stock have no Preemptive and Similar Rights. The holders of common stock have no Redemption/Put Rights. There are no Preferred Stock Our board of directors has the authority to issue shares of preferred stock from time to time on terms it may one Warrants (Restated) As of December 31, 2020, 6,325,000 556,313 Each public warrant entitles the holder thereof to purchase one of $11.50 No We may not of $0.01 ● if, and only if, the reported last sale price of the common stock equals or exceeds $21.00 20 30 third ● if, and only if, there is a current registration statement in effect with respect to the issuance of the shares of Common Stock underlying such Public Warrants at the time of redemption and for the entire 30 ● at any time while the public warrants are exercisable ● upon not 30 The private warrants are substantially similar to the public warrants except such private warrants; ● are exercisable for cash or on a cashless basis, at the holder's option ● cannot be redeemed by us, so long as they are still held by the initial purchasers or their affiliates. ● The redemption price is to be calculated as the 10 one The private warrants are identical to the public warrants except that such private warrants will be exercisable for cash or on a cashless basis, at the holder's option, and will not In no The Company classified the private warrants pursuant to ASC 815 third December 14, 2020, $2.0 December 31, 2020 no The exercise price and number of shares of common stock issuable on exercise of the warrants may Further, there were assumed warrants outstanding to purchase an aggregate of 126,268 Common stock warrants 2020 In July 2020, 120,456 five $22.99 “2020 2020 2020 $1,178,182, Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 % The 2020 December 31, 2020. 2016 The Company issued warrants in connection with the 2016 “2016 5,812 April 28, 2022. The fair value of the warrants was originally estimated to be approximately $101,000 not In connection with the Business Combination, the strike price was set at $42.29 0.152268. Immediately following the Business Combination, the fair value of the warrant was estimated to be $7,395 0.36%. 126% 1.4 zero not not Upon the valuation of the warrants, the Company reclassed the warrant liability to additional paid-in capital with $94,175 December 31, 2020. Originally, the warrants were classified as a liability due to the contingent nature of the exercise price and marked to fair value at each reporting period. Upon establishment of a set exercise price, the Company determined that under ASC 480,

Note 10 - Stock Option Plan and

Note 10 - Stock Option Plan and Stock-based Compensation	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	10. 2006 Reviva's board of directors adopted, and Reviva's stockholders approved, the Reviva Pharmaceuticals, Inc. 2006 August 2006. 2006 422 not 2016, no 2006 Upon the Business Combination, the Reviva Pharmaceuticals, Inc. 2006 2006 “2006 2006 2006 65,471 no 2006 2020 On December 14, 2020, 2020 “2020 2020 may As of December 31, 2020, 461,587 may 2020 January 1st not ten January 1st 2020 January 1, 2030, ten 10% December 31st 2020 may 461,587. There was no 2020 December 31, 2020. Activity under the 2006 December 31, 2020 2019. ​ Shares available for Grant Number of Shares Outstanding Weighted average exercise price per share Balance, December 31, 2018 329,025 127,778 $ 15.37 Options cancelled 14,846 (14,846 ) — Balance, December 31, 2019 343,871 112,932 $ 15.37 Options cancelled 47,461 (47,461 ) — Effect of plan amendment on business combination (391,332 ) — — Balance, December 31, 2020 — 65,471 $ 16.86 Vested, December 31, 2020 — 65,471 $ 16.86 Vested and expected to vest, December 31, 2020 — 65,471 $ 16.86 Shares outstanding under the 2006 December 31, 2020: Options Weighted Shares Weighted 48,724 1.85 48,724 $ 11.89 16,747 3.93 16,747 $ 31.33 65,471 2.38 65,471 $ 16.86 During the years ended December 31, 2020 2019, no no

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	11. Clinical trials Since 2010, 2 may third not $5 may 30 Indemnification From time to time, in its normal course of business, the Company may may third may not no may Operating Leases The Company has adopted ASC 842 one twelve 19925 100, 95014. $1,200 January 31, 2021 12

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The summary of significant accounting policies presented below is designed to assist in understanding the Company's financial statements. Such financial statements and accompanying notes are the representations of Company's management, who is responsible for their integrity and objectivity.
Consolidation, Policy [Policy Text Block]	Principals of consolidation The accompanying consolidated financial statements include the accounts of the Reviva Pharmaceuticals Holdings, Inc. and its wholly owned subsidiary Reviva Pharmaceuticals, India Pvt Ltd. The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. All transactions and balances between the parent and its subsidiary have been eliminated in consolidation.
Reclassification, Comparability Adjustment [Policy Text Block]	Restatement of previously issued financial statements As part of the Business Combination, the Company originally completed a comprehensive evaluation that supported the equity classification of the private warrants that were initially issued by Tenzing. Subsequent to filing our original report on March 21, 2021, April 12, 2021. 815, 815 815” December 14, 2020 December 31, 2020. $2.0 December 14, 2020. December 31, 2020 December 31, 2020 not not The table below sets forth the consolidated balance sheet for affected financial statement line items, balances originally reported as of December 31, 2020: As of December 31, 2020 Reported Restated Warrant liabilities $ - $ 1,963,785 Total liabilities 1,332,743 3,296,528 Additional paid-in capital 65,738,705 63,774,920 Total stockholders' equity (deficit) 7,429,535 5,465,750 In addition to the restated consolidated financial statement, the information contained in Notes 9
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are not
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk and other risks and uncertainties Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company's cash are held in demand deposit form by one not The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash The Company considers all highly liquid investments purchased with an original maturity at the date of purchase of three December 31, 2020, 2019, two may,
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment The Company capitalizes expenditures related to property and equipment, subject to a minimum rule, that have a useful life greater than one 1 2 three five
Lessee, Leases [Policy Text Block]	Leases In February 2016, 2016 2 no
Research and Development Expense, Policy [Policy Text Block]	Research and development costs Research and development costs are charged to operating expenses as incurred. Research and development costs include, but are not
Selling, General and Administrative Expenses, Policy [Policy Text Block]	General and Administrative costs General and administrative costs are charged to operating expenses as incurred. General and administrative costs include, but are not
Income Tax, Policy [Policy Text Block]	Income taxes The Company utilizes FASB ASC 740, not” not The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. In evaluating the ability recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its opening results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. The Company generated a deferred tax asset through net operating loss carry-forward. However, a valuation allowance of 100% not
Share-based Payment Arrangement [Policy Text Block]	Stock-based compensation Stock-based compensation is calculated based on the requirements of the Share-Based Payment Topic of ASC 718 505, 50, The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The determination of the fair value of stock-based payment awards on the date of grant is affected by the stock price as well as assumptions regarding a number of complex and subjective variables. These variables include expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rates, and expected dividends as under: • Expected term ​ • Expected volatility ​ • Expected dividend no ​ • Risk-free interest rate zero ​ As of January 1, 2019, No. 2018 07, 718 not not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Due to their short maturities, the carrying amounts for cash and cash equivalents, accounts payable, and accrued expenses approximate their fair value. Non-current assets are primarily related to certain advances with carrying values that approximate their fair values. Fair Value Measurements of Warrants ASC 820 820 820 1 2 three 1 3 The three 820 • Level 1 — Quoted 1 ​ • Level 2 — Directly not 2 not ​ • Level 3 — Unobservable no ​ In determining the fair value of warrants, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The following table presents information about the Company's liabilities that are measured at fair value on a recurring basis as of December 31, 2020 Description Level December 31, 2020 Warrant liabilities 2 1,973,785 The key inputs used in valuing the warrant liabilities are as follows: Risk-free interest rate - 0.36% Expected life – 5 Expected volatility – 56.6% Exercise price – $11.50 Stock price – $8.75
Beneficial Conversion Feature [Policy Text Block]	Beneficial Conversion Features In accordance with FASB ASC 470 20,

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	As of December 31, 2020 Reported Restated Warrant liabilities $ - $ 1,963,785 Total liabilities 1,332,743 3,296,528 Additional paid-in capital 65,738,705 63,774,920 Total stockholders' equity (deficit) 7,429,535 5,465,750

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	​ 2020 2019 Computer equipment $ 32,500 $ 32,500 Furniture and fixtures 9,208 9,208 Accumulated depreciation (41,708 ) (41,117 ) Property and equipment, net $ - $ 591

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	December 31, 2020 2019 Statutory federal income tax rate (794,343 ) (177,562 ) State income taxes, net of federal tax benefits (114,864 ) (79,257 ) Stock Based Compensation - 27,940 Foreign Rate Differential (45 ) - Warrant Expense 227,651 - Beneficial conversion feature related to notes 201,953 - Other Permanent Differences 19,204 473 Valuation allowance 461,244 229,206 800 800
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, 2020 2019 NOL carryforwards 9,177,607 8,711,765 Accruals and reserves 10,898 14,402 Stock compensation 237,976 83,472 Fixed assets/capitalized start-up costs 3,332 3,589 9,429,813 8,813,228 Valuation allowance (9,429,813 ) (8,813,228 ) Net deferred tax assets - - Deferred income taxes - -

Note 9 - Stockholders' Equity_2

Note 9 - Stockholders' Equity (Deficit) (Restated) (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	Assumptions Common stock value $ 2.25 Expected life (in years) 3 Risk-free interest rate 0.28 % Expected dividend yields 0 % Volatility 126 %

Note 10 - Stock Option Plan a_2

Note 10 - Stock Option Plan and Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	​ Shares available for Grant Number of Shares Outstanding Weighted average exercise price per share Balance, December 31, 2018 329,025 127,778 $ 15.37 Options cancelled 14,846 (14,846 ) — Balance, December 31, 2019 343,871 112,932 $ 15.37 Options cancelled 47,461 (47,461 ) — Effect of plan amendment on business combination (391,332 ) — — Balance, December 31, 2020 — 65,471 $ 16.86 Vested, December 31, 2020 — 65,471 $ 16.86 Vested and expected to vest, December 31, 2020 — 65,471 $ 16.86
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	Options Weighted Shares Weighted 48,724 1.85 48,724 $ 11.89 16,747 3.93 16,747 $ 31.33 65,471 2.38 65,471 $ 16.86

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation (Details Textual)	12 Months Ended
	Dec. 31, 2020USD ($)	Dec. 14, 2020USD ($)	Dec. 31, 2019USD ($)
Additional Paid in Capital, Ending Balance	$ 63,774,920		$ 18,644,683
Measurement Input, Risk Free Interest Rate [Member]
Derivative Liability, Measurement Input	0.0036
Measurement Input, Expected Term [Member]
Derivative Liability, Measurement Input	5
Measurement Input, Price Volatility [Member]
Derivative Liability, Measurement Input	0.566
Measurement Input, Exercise Price [Member]
Derivative Liability, Measurement Input	11.5
Measurement Input, Share Price [Member]
Derivative Liability, Measurement Input	8.75
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Liability, Total	$ 1,973,785
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Revision of Prior Period, Adjustment [Member]
Additional Paid in Capital, Ending Balance	$ (2,000,000)	$ (2,000,000)

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies and Basis of Presentation - Restatement (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Warrant liabilities	$ 1,963,785	$ 101,525
Total liabilities	3,296,528	6,814,030
Additional paid-in capital	63,774,920	18,644,683
Total stockholders’ equity (deficit)	5,465,750	$ (6,811,430)	$ (5,964,598)
Previously Reported [Member]
Warrant liabilities
Total liabilities	1,332,743
Additional paid-in capital	65,738,705
Total stockholders’ equity (deficit)	$ 7,429,535

Note 3 - Business Combination (

Note 3 - Business Combination (Details Textual) $ / shares in Units, $ in Thousands	Dec. 14, 2020USD ($)$ / sharesshares	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.0001	$ 0.0001
Reviva Pharmaceuticals, Inc. [Member]
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.0001
Additional Shares to be Issued to Security Holders, Contingent on Stock Price Performance (in shares) | shares	1,000,000
Stock Price Performance, Milestone Period (Year)	3 years
Threshold Closing Price for Specified Number of Trading Days (in dollars per share)	$ 15
Threshold Trading Days for Sale of Shares (Day)	20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)	30 days
Goodwill, Ending Balance | $	$ 0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total | $	$ 0
Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Common Stock into Company's Common Stock [Member]
Conversion of Stock, Conversion Rate	0.152268
Reviva Pharmaceuticals, Inc. [Member] | Conversion of Reviva Preferred Stock into Company's Common Stock [Member]
Conversion of Stock, Conversion Rate	0.414647

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Depreciation, Total	$ 591	$ 645

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Accumulated depreciation	$ (41,708)	$ (41,117)
Property and equipment, net		591
Computer Equipment [Member]
Computer equipment	32,500	32,500
Furniture and Fixtures [Member]
Computer equipment	$ 9,208	$ 9,208

Note 5 - Employee Benefit Plan

Note 5 - Employee Benefit Plan (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0

Note 6 - Convertible Promisso_2

Note 6 - Convertible Promissory Notes (Details Textual) - USD ($)	Dec. 14, 2020	Dec. 10, 2020	Jan. 02, 2020	Nov. 01, 2018	Jun. 01, 2016	Oct. 31, 2020	Dec. 31, 2020	Dec. 15, 2020	Aug. 01, 2020	Mar. 01, 2020	Dec. 31, 2019
The 2018 Contingent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)				5 years
Warrants and Rights Outstanding											$ 0
The 2020 Contingent Warrants [Member]
Warrants and Rights Outstanding, Term (Year)										5 years
Warrants and Rights Outstanding							$ 0
Conversion of 2016 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	576,836
Conversion of 2018 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	56,461
Conversion of 2020 Notes into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	113,422
Conversion of Reviva Contingent Interim Period Note into Common Stock [Member] | Closing [Member]
Conversion of Stock, Shares Issued (in shares)	261,626
Conversion of 2016 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		3,788,461
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.329698
Conversion of 2018 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		370,811
Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 0.831018
Conversion of 2018 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.330045
Conversion of 2020 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)		744,916
Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount of at Least $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.831009
Conversion of 2020 Notes into Common Stock with Aggregate Principal Amount Less Than $50,000 [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)		$ 1.32977
Conversion of August 2020 to October 2020 Notes into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						601,632
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.831063
Conversion of Reviva Contingent Interim Period Note into Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)						1,718,280
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 1.163953
The 2016 Notes [Member]
Debt Instrument, Face Amount					$ 4,795,088
Qualified Financing, Minimum Threshold					$ 5,000,000
Qualified Financing, Discount Rate to Price Paid by Investors					20.00%
Pre-offering Valuation Prior to Qualified Financing Event					$ 85,000,000
Debt Instrument, Interest Rate, Stated Percentage					8.00%
Debt Instrument, Term (Month)					1 year
Debt Instrument, Debt Default, Interest Rate							12.00%
Convertible Notes Payable, Total		$ 1,200,000									3,490,087
Interest Payable											$ 1,192,496
Debt Instrument, Convertible, Beneficial Conversion Feature		0
Warrants and Rights Outstanding							$ 7,395
The 2016 Notes [Member] | One Investor [Member]
Debt Instrument, Interest Rate, Stated Percentage			5.50%
Interest Payable, Current			$ 242,236					$ 79,840
Debt Instrument, Fee Amount			5,000
Repayments of Convertible Debt			$ 1,447,236
The 2018 Notes [Member]
Debt Instrument, Face Amount				$ 275,000
Qualified Financing, Discount Rate to Price Paid by Investors				20.00%
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Instrument, Term (Month)				180 days
Debt Instrument, Debt Default, Interest Rate							8.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		159,025
Debt Instrument, Renewal Term (Month)				180 days
The 2020 Notes [Member]
Debt Instrument, Face Amount										$ 610,000
Qualified Financing, Discount Rate to Price Paid by Investors										20.00%
Debt Instrument, Convertible, Beneficial Conversion Feature		$ 317,730
August 2020 to October 2020 Notes [Member]
Debt Instrument, Face Amount									$ 500,000
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 274,083
Reviva Contingent Interim Period Note [Member]
Debt Instrument, Face Amount									$ 2,000,000
Debt Instrument, Convertible, Beneficial Conversion Feature						$ 210,842

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 616,858
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	0	$ 0
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0	0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	39,500,000
Operating Loss Carryforwards, Subject to Expiration	35,300,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	$ 12,600,000

Note 7 - Income Taxes - Provisi

Note 7 - Income Taxes - Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Statutory federal income tax rate	$ (794,343)	$ (177,562)
State income taxes, net of federal tax benefits	(114,864)	(79,257)
Stock Based Compensation		27,940
Foreign Rate Differential	(45)
Warrant Expense	227,651
Beneficial conversion feature related to notes	201,953
Other Permanent Differences	19,204	473
Valuation allowance	461,244	229,206
Income Tax Expense (Benefit), Total	$ 800	$ 800

Note 7 - Income Taxes - Deferre

Note 7 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
NOL carryforwards	$ 9,177,607	$ 8,711,765
Accruals and reserves	10,898	14,402
Stock compensation	237,976	83,472
Fixed assets/capitalized start-up costs	3,332	3,589
Deferred Tax Assets, Gross, Total	9,429,813	8,813,228
Valuation allowance	(9,429,813)	(8,813,228)
Net deferred tax assets

Note 8 - Loss Per Share (Detail

Note 8 - Loss Per Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Common Stock, Shares, Outstanding, Ending Balance (in shares)	9,231,737
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	7,007,581	7,007,581
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	65,471	65,471
Earn-out Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,000,000	1,000,000

Note 9 - Stockholders' Equity_3

Note 9 - Stockholders' Equity (Deficit) (Restated) (Details Textual)	1 Months Ended	12 Months Ended
	Sep. 30, 2020shares	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)$ / sharesshares	Dec. 14, 2020USD ($)	Jul. 31, 2020USD ($)$ / sharesshares	Jun. 01, 2016USD ($)$ / sharesshares
Common Stock, Shares Authorized (in shares)		115,000,000	115,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized (in shares)		10,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares		$ 0.0001
Common Stock, Shares, Outstanding, Ending Balance (in shares)		9,231,737
Preferred Stock, Shares Outstanding, Ending Balance (in shares)		0
Deferred Compensation Arrangement with Individual, Shares Issued (in shares)	38,992
Additional Paid in Capital, Ending Balance | $		$ 63,774,920	$ 18,644,683
Fair Value Adjustment of Warrants | $		1,084,052	$ (6,409)
The 2016 Notes [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)						0.152268
Warrants and Rights Outstanding | $		$ 7,395
The 2016 Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0.0036
The 2016 Notes [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input		1.26
The 2016 Notes [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input		1.4
The 2016 Notes [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input		0
Revision of Prior Period, Adjustment [Member]
Additional Paid in Capital, Ending Balance | $		$ (2,000,000)		$ (2,000,000)
Public Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		6,325,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares		$ 11.50
Class of Warrant or Right, Redemption Price Per Share (in dollars per share) | $ / shares		0.01
Threshold Closing Price for Specified Number of Trading Days (in dollars per share) | $ / shares		$ 21
Threshold Trading Days for Sale of Shares (Day)		20 days
Threshold Consecutive Trading Days for Sale of Shares (Day)		30 days
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		126,268
Private Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)		556,313
The 2020 Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)					120,456
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares					$ 22.99
Warrants and Rights Outstanding, Term (Year)					5 years
Warrants and Rights Outstanding | $					$ 1,178,182
The 2020 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0.0028
The 2020 Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input					1.26
The 2020 Warrants [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input					3
The 2020 Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input					0
The 2016 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 42.29
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						5,812
Warrants and Rights Outstanding | $						$ 101,000
The 2016 Warrants [Member] | General and Administrative Expense [Member]
Fair Value Adjustment of Warrants | $		$ 94,175

Note 9 - Stockholders' Equity_4

Note 9 - Stockholders' Equity (Deficit) (Restated) - Warrant Assumptions (Details) - The 2020 Warrants [Member]	Jul. 31, 2020
Measurement Input, Share Price [Member]
Warrant, assumptions	2.25
Measurement Input, Expected Term [Member]
Warrant, assumptions	3
Measurement Input, Risk Free Interest Rate [Member]
Warrant, assumptions	0.0028
Measurement Input, Expected Dividend Rate [Member]
Warrant, assumptions	0
Measurement Input, Price Volatility [Member]
Warrant, assumptions	1.26

Note 10 - Stock Option Plan a_3

Note 10 - Stock Option Plan and Stock-based Compensation (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	65,471	112,932	127,778
Share-based Payment Arrangement, Expense	$ 0	$ 0
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 0	$ 0
Equity Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)	65,471
Equity Incentive Plan 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	461,587
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Percent of Increase	10.00%
Equity Incentive Plan 2020 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)	461,587

Note 10 - Stock Option Plan a_4

Note 10 - Stock Option Plan and Stock-based Compensation - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Beginning balance, number of shares outstanding (in shares)	112,932	127,778
Options cancelled (in shares)	(47,461)	(14,846)
Ending balance, number of shares outstanding (in shares)	65,471	112,932
Vested (in shares)	65,471
Vested and expected to vest (in shares)	65,471
Beginning balance, weighted average exercise price per share (in dollars per share)	$ 15.37	$ 15.37
Options cancelled, weighted average exercise price per share (in dollars per share)
Ending balance, weighted average exercise price per share (in dollars per share)	16.86	$ 15.37
Vested, weighted average exercise price per share (in dollars per share)	16.86
Vested and expected to vest, weighted average exercise price per share (in dollars per share)	$ 16.86
Share-based Payment Arrangement, Option [Member]
Beginning balance, number of shares available for grant (in shares)	343,871	329,025
Number of shares available for grant, options cancelled (in shares)	47,461	14,846
Effect of plan amendment on business combination (in shares)	(391,332)
Ending balance, number of shares available for grant (in shares)		343,871

Note 10 - Stock Option Plan a_5

Note 10 - Stock Option Plan and Stock-based Compensation - Shares Outstanding Under Option Plan (Details) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Options outstanding (in shares)	65,471	112,932	127,778
Weighted average remaining contractual life (Year)	2 years 138 days
Shares exercisable (in shares)	65,471
Weighted average exercise price (in dollars per share)	$ 16.86
Range 1 [Member]
Options outstanding (in shares)	48,724
Weighted average remaining contractual life (Year)	1 year 310 days
Shares exercisable (in shares)	48,724
Weighted average exercise price (in dollars per share)	$ 11.89
Range 2 [Member]
Options outstanding (in shares)	16,747
Weighted average remaining contractual life (Year)	3 years 339 days
Shares exercisable (in shares)	16,747
Weighted average exercise price (in dollars per share)	$ 31.33

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual)	12 Months Ended
	Dec. 31, 2020USD ($)
Corporate Office Lease [Member]
Lessee, Operating Lease, Term of Contract (Month)	1 year
Lessee, Operating Lease, Monthly Lease Payment	$ 1,200
Lessee, Operating Lease, Renewal Term (Month)	1 year
Minimum [Member]
General Product Liability Insurance	$ 5,000,000